ArriVent BioPharma (AVBP) News Today $20.82 +1.51 (+7.82%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$20.82 0.00 (0.00%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVBP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 6 at 2:23 AM | americanbankingnews.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by AnalystsOctober 6 at 2:21 AM | marketbeat.comArriVent BioPharma Taps Brent S. Rice as Chief Commercial OfficerSeptember 29, 2025 | msn.comArriVent BioPharma, Inc.: ArriVent Appoints Brent S. Rice as Chief Commercial OfficerSeptember 26, 2025 | finanznachrichten.deArriVent Biopharma appoints Brent Rice as chief commercial officerSeptember 22, 2025 | msn.comArriVent Appoints Brent S. Rice as Chief Commercial OfficerSeptember 22, 2025 | globenewswire.comGoldman Sachs Group Inc. Has $1.42 Million Stake in ArriVent BioPharma, Inc. $AVBPSeptember 21, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% - Here's WhySeptember 12, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of "Buy" from BrokeragesSeptember 12, 2025 | marketbeat.comArriVent Biopharma presents proof-of-concept data from Phase 1b FURTHER trialSeptember 9, 2025 | msn.comArrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on ...September 9, 2025 | finance.yahoo.comArrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung CancerSeptember 9, 2025 | globenewswire.comArriVent BioPharma, Inc. $AVBP Position Boosted by Infinitum Asset Management LLCSeptember 9, 2025 | marketbeat.comNuveen LLC Takes $819,000 Position in ArriVent BioPharma, Inc. $AVBPSeptember 4, 2025 | marketbeat.comWellington Management Group LLP Purchases 19,427 Shares of ArriVent BioPharma, Inc. $AVBPSeptember 2, 2025 | marketbeat.comWhat is B. Riley's Estimate for AVBP Q3 Earnings?August 30, 2025 | marketbeat.comArriVent BioPharma, Inc. $AVBP Shares Acquired by Vanguard Group Inc.August 30, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Raised to "Strong-Buy" at B. RileyAugust 29, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Rating Increased to Hold at Zacks ResearchAugust 22, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Buy" by BrokeragesAugust 18, 2025 | marketbeat.comQ3 EPS Estimate for ArriVent BioPharma Raised by AnalystAugust 17, 2025 | marketbeat.comCooperman’s Omega bought Atlas Energy and ArriVent in Q2August 14, 2025 | msn.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 4.3% Following Weak EarningsAugust 13, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Announces Quarterly Earnings ResultsAugust 12, 2025 | marketbeat.comArriVent Biopharma price target lowered to $33 from $40 at CitiAugust 12, 2025 | msn.comPositive Growth Trajectory and Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Clinical Data and Strategic DevelopmentAugust 11, 2025 | tipranks.comArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | finanznachrichten.deArriVent BioPharma Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | globenewswire.comArriVent BioPharma (AVBP) to Release Earnings on WednesdayAugust 7, 2025 | marketbeat.comLifesci Capital Issues Optimistic Estimate for AVBP EarningsJuly 23, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Rating of "Buy" from AnalystsJuly 23, 2025 | marketbeat.comArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at HC WainwrightJuly 22, 2025 | marketbeat.comBuy Rating for ArriVent BioPharma: Promising Potential of Lead Candidate and Solid Financial PositionJuly 21, 2025 | tipranks.comArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026July 21, 2025 | globenewswire.comArriVent BioPharma, Inc.: Promising Developments and Strategic Advancements Drive Buy RatingJuly 17, 2025 | tipranks.comArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated by Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comArriVent BioPharma expects to raise $75M from stock saleJuly 2, 2025 | bizjournals.comArriVent BioPharma (NASDAQ:AVBP) Sees Large Volume Increase - Time to Buy?July 2, 2025 | marketbeat.comArriVent BioPharma prices $75M equity offeringJuly 2, 2025 | msn.comArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded WarrantsJuly 1, 2025 | globenewswire.comArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded WarrantsJuly 1, 2025 | globenewswire.comArriVent BioPharma (NASDAQ:AVBP) Trading Down 4.5% - Should You Sell?June 30, 2025 | marketbeat.comArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Buy" by BrokeragesJune 28, 2025 | marketbeat.comClear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy RecommendationJune 26, 2025 | msn.comWhat is Lifesci Capital's Estimate for AVBP FY2025 Earnings?June 26, 2025 | marketbeat.comAVBP - ArriVent BioPharma Inc Sustainability - MorningstarJune 25, 2025 | morningstar.comMArriVent BioPharma Reports Promising Results from Phase 1b Trial for Firmonertinib in NSCLCJune 25, 2025 | msn.comQ2 Earnings Forecast for AVBP Issued By Lifesci CapitalJune 25, 2025 | marketbeat.comSG Americas Securities LLC Boosts Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP)June 25, 2025 | marketbeat.comArriVent BioPharma (NASDAQ:AVBP) Shares Gap Up on Analyst UpgradeJune 24, 2025 | marketbeat.com Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVBP Media Mentions By Week AVBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVBP News Sentiment▼0.400.63▲Average Medical News Sentiment AVBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVBP Articles This Week▼33▲AVBP Articles Average Week Get the Latest News and Ratings for AVBP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ArriVent BioPharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Ultragenyx Pharmaceutical News Today Apellis Pharmaceuticals News Today MorphoSys News Today Kiniksa Pharmaceuticals International News Today Immunovant News Today Organon & Co. News Today HUTCHMED News Today Mineralys Therapeutics News Today Tarsus Pharmaceuticals News Today Alvotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVBP) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
